仙琚制药：收到行政处罚决定书 被罚没1.95亿元

Core Viewpoint - Xianju Pharmaceutical has been fined a total of 195 million yuan due to anti-competitive practices related to the pricing of dexamethasone phosphate sodium raw materials, which involved collusion with competitors [1] Summary by Relevant Sections Administrative Penalty - The company received an administrative penalty decision from the Tianjin Municipal Market Supervision Administration on April 30, 2025 [1] - The total penalty includes the confiscation of illegal gains amounting to 23.7467 million yuan and a fine of 171 million yuan, which is 8% of the company's sales in 2023, leading to a total of 195 million yuan in penalties [1] Impact on Company Operations - The main responsible person of the company, Zhang Yusong, has been fined 600,000 yuan [1] - The company confirmed that this penalty does not trigger any major illegal circumstances that would lead to forced delisting, although it will have a negative impact on the current financial statements [1] - Despite the penalty, the company asserts that it will not affect normal operations and development [1] Compliance Measures - In response to the penalty, the company has developed antitrust compliance management guidelines and an employee compliance manual [1] - The company has initiated a comprehensive risk assessment and specialized training to strengthen antitrust compliance management [1]